No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (DGX) and Myriad Genetics (MYGN)
A Quick Look at Today's Ratings for Myriad Genetics(MYGN.US), With a Forecast Between $11 to $19
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Released Its Yearly Earnings: Here's What Analysts Think
Myriad Genetics Reports Strong Growth Amid Challenges
Express News | Myriad Genetics Shares Are Trading Lower Following a Q4 Revenue Miss and FY25 Revenue Guidance Below Estimates. The Stock May Also Be Trading on Weakness After It Announced It Will Face Cost Restructuring Following UnitedHealthcare's Decision to End...
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
